Debrisoquine oxidation polymorphism in patients with chronic inflammatory bowel disease.

doi:10.3109/07853899509002468

Back to search

Article

Debrisoquine oxidation polymorphism in patients with chronic inflammatory bowel disease.

Annals of medicine - 1 Oct 1995

Ladero J M, Benítez J, Serrano M, García-Paredes J, Diaz-Rubio M

Abstract excerpt

Polymorphic hydroxylation of debrisoquine (DBQ) is a Mendelian genetic trait related to the risk of suffering some spontaneous disorders. To elucidate whether such a relation exists between this polymorphism and chronic inflammatory bowel disease (CIBD), 67 (39 males) patients with ulcerative col...

Topics

Adult
Colitis, Ulcerative
Crohn Disease
Debrisoquin
Female
Humans
Male
Oxidation-Reduction
Phenotype
Polymorphism, Genetic
Risk Factors

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.